Blue Diamond Ventures Inc (BLDV)

[JPS02]

Identifying the Cannabis Compounds that Kill Cancer

Published on Jul 17, 2018

In our latest CannMed speaker interview, David Meiri provides some amazing insight into how he and his team are working to understand the specific cannabis compounds that can be used to kill cancer cells. What they have found so far is fascinating.

By testing different cannabis extracts on cancer cells with specific genetic mutations, they can identify which cannabis strains are effective in killing a certain type of cancer cell. From there, they dig deeper into the cell’s mechanisms to figure out how the cannabis compounds block, activate, or change the pathways and determine the minimum compounds needed to produce the effect.

Using this approach Dr. Meiri and his team have found a specific combination of three compounds that kills leukemia cells. Interestingly, if one of those compounds is excluded from the extract, it will not kill the cell. This finding seems to confirm the theory of an entourage effect; however, all 100+ compounds found in the cannabis plant are not needed in this case. What’s even more interesting is that the effective compounds they identified are not the major cannabinoids or terpenes we are all familiar with. In fact, one compound hasn’t even been named in the literature!

Watch the video below to learn more about Dr. Meiri’s work, and be sure to purchase tickets to CannMed 2018 where he will share the team’s latest findings!

1. In this YT interview clip from July 2018, Dr. Meiri emphasizes that there is specificity and certain amount of cannabis required between the strain extract and their effects to kill different cancers. Dr. Meiri indicates that they tested and analyzed different mutations to identify and understand the specific strains and compounds of cannabinoids that could treat the diseases effectively based on the various receptors set-up's that can be used.

2. I think the technology licensing model and the CannTech alliance that BLDV mentioned in the 8/2/18 PR will rely on this type of research knowledge coming out of Israel to ensure its success:

https://backend.otcmarkets.com/otcapi/company/dns/news/document/32175/content

3. It is useful to read the 'Medical Cannabis Research Group' real treatment clinical trials example link provided in BLDV's 8/2/18 PR about a sponsored research agreement with Dr. Meiri in Australia which I think highlights the benefits of Dr. Meiri's efforts to possibly help support the technology licensing model mentioned in the 8/2/18 BLDV PR. To this end, I think it will be interesting to see if there will be any agreements put in place for North America through Cann10 NA given the recent developments. Notice the timing of what is mentioned in the BLDV PR and when the interview above was published.

https://backend.otcmarkets.com/otcapi/company/dns/news/document/32175/content

http://www.abnnewswire.net/press/en/94082/Queensland-Bauxite-Ltd-(ASX-QBL)-Ground-breaking-Discovery-in-Medicinal-Cannabis-Research-94082.html

4. Note that Dr. Meiri is presenting at CannX along with the BLDV CEO:

https://cannx.org/2018/agenda-(2)/speakers#.W2fAohpzbIU

Go BLDV!